TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
SVRA

Savara Inc

Healthcare · Biotechnology

5.30$ -2.8% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Cash Flow

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Cash Flow SVRA
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
+71.8% +137.0% +4.9% +44.9% +92.0% -31.4% -47.0% -54.5% -53.9% +68.8% -33.1%
+31.6% -92.2% +164.1% +577.0% +18.8% +15.0% -36.2% -37.4% +104.7% +136.0% +46.3%
+73.4% +135.7% -62.9% +696.0% +69.7% -67.4% -52.9%
+60.0% -61.4% -235.6% -65.4% -301.3% +324.3% -55.1% +173.4%
+12.2% -95.2% +6,087.5% -71.5% +5.0% +2,125.7% -98.3% -84.2% +3,188.9% -91.6% -12.0%
+605.8% -100.2% +863,837.5% -80.3% -42.5% -867.2% -208.5% -30.1% -53.8%
-94.2% +868.1% +371.9% -49.2% +18.5% -96.1% -103.7% -96.2% +40,166.7% -17.6% +416.6%
+48.0% -179.6% -38.9% -100.5% +1,153.7% -100.0% -100.0%
-51.0% -69.5% +1,973.3% -48.0% -0.5% -93.3% +3,174.8% -99.9% +95,049.4% +42.0% +17.2%
-226.0% -75.1% +1,069.9% -205.6% +62.5% -241.1%

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?